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HIGHLIGHTS
•
•
•

Delaying adjuvant radiation treatment >8 weeks after hysterectomy may increase the risk of cancer recurrence.
The rate of isolated recurrences in the vagina was significantly higher with delayed radiation treatment.
Timely initiation of adjuvant radiation therapy after hysterectomy is recommended.

ABSTRACT
Objective The benefits of adjuvant radiation treatment
after hysterectomy have been confirmed in select patients
with early-stage endometrial carcinoma. The goal of this
study was to evaluate the prognostic impact of the time
interval between hysterectomy and starting adjuvant
radiation treatment in patients with early-stage endometrial
carcinoma.
Methods Our database was searched for women with
early-stage endometrioid endometrial cancer who received
adjuvant radiation therapy after hysterectomy. The patients
were classified into two groups based on the time interval
to adjuvant radiation therapy (≤8 weeks or >8 weeks) after
hysterectomy. Recurrence-free survival, disease-specific
survival, and overall survival were compared between the
two groups.
Results Four hundred and sixty patients were identified.
Median follow-up was 70.5 months (range 1–360). One
hundred and seventy-six patients (38%) were 2009
International Federation of Gynecology and Obstetrics
stage IA, 207 (45%) stage IB, and 77 (17%) stage II. Three
hundred and fifty-four women (77%) received adjuvant
radiation therapy within 8 weeks after hysterectomy. There
was no statistically significant difference between the two
groups in baseline demographics, disease and treatment
characteristics, except for the modality of adjuvant radiation
therapy. Patients who received adjuvant radiation therapy
within 8 weeks experienced significantly less disease
recurrence (9% vs 18%; p=0.01) and particularly less
isolated vaginal recurrence (0% vs 6%, p=0.04). Five-year
recurrence-free survival was 89% versus 80% (p=0.04),
5-year disease-specific survival was 93% for both groups,
and 5-year overall survival was 86% versus 85% for patients
who received adjuvant radiation therapy ≤8 and >8 weeks,
respectively (p=0.88).
Conclusion Our study suggests that delaying adjuvant
radiation therapy beyond 8 weeks after hysterectomy is
associated with significantly more cancer recurrences for
women with early-stage endometrial carcinoma.

INTRODUCTION
Endometrial cancer is the most common gynecologic
malignancy in the USA, with an estimated incidence

of 65 620 for the year 2020.1 Complete surgical
staging is the primary treatment of choice, and adjuvant radiation therapy is indicated for patients with
early-stage endometrial cancer who are at high risk
for disease recurrence.2–4 Three large randomized
controlled trials (GOG 99,3 PORTEC 1–22 4) that established the role of adjuvant radiation therapy in early-
stage endometrial cancer mandated that adjuvant
radiation therapy be initiated no more than 8 weeks
after surgery. However, in clinical practice, the time
interval from surgery to the initiation of adjuvant
radiation therapy can vary depending on a variety
of patient- and/or institution-related factors; therefore, some patients do not receive adjuvant radiation
therapy within the recommended 8-week window
after hysterectomy.
The prognostic significance of the time interval
between hysterectomy and the starting date of adjuvant radiation therapy in women with endometrial
cancer has been studied in a few published reports.
The investigators of these studies showed that a
delay in the initiation of adjuvant radiation therapy
after hysterectomy may be associated with more
cancer recurrences.5–9 While useful, these studies
were clouded with some limitations such as inclusion
of patients with advanced-stage disease5–7 or non-
endometrioid histology (such as clear cell carcinoma
and papillary serous carcinoma),6 8 use of various
time interval cut-offs (such as 6 weeks,5 8 8 weeks,9
and 9 weeks6 7), inclusion of patients who received
adjuvant chemotherapy,8 and lack of information on
disease recurrence8 9 or robust multivariate statistical
analysis for the impact of time interval on recurrence.7
In order to assess the prognostic impact of adjuvant
radiation therapy delay as defined by large prospective trials, the goal of this study was to compare
survival endpoints including recurrence-free survival
in patients with early-stage endometrial cancer solely
of endometrioid type using 8 weeks as a cut-off for
defining adjuvant radiation treatment delay.
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Table 1 Patient demographics, disease and treatment characteristics for the study cohort of 460 women
Characteristics

≤8 weeks
(n=354)

>8 weeks
(n=106)

P value

Median age, years (range)
Median BMI (range)

66.0 (26–91)
32.6 (17.5–69.9)

65 (40–87)
32.8 (19.7–60.4)

0.83
0.86

Race
272 (77%)

80 (75%)

 AA

72 (20%)

22 (21%)

 Other

10 (3%)

4 (4%)

 White

Median Charlson comorbidity index (range)

0 (0–8)

0.87

1 (0–10)

0.21
0.93

FIGO stage
 IA

134 (38%)

42 (40%)

 IB

161 (45%)

46 (43%)

 II

59 (17%)

18 (17%)

 1

133 (38%)

44 (42%)

 2

140 (40%)

41 (39%)

 3

81 (23%)

21 (20%)

Positive LVSI

108 (31%)

35 (33%)

0.62

Lymph node dissection

Grade
0.71

299 (84%)

82 (77%)

0.09

Median number of total LNs dissected

9 (1–68)

9 (1–66)

0.24

Median number of pelvic LNs dissected

8 (1–44)

8 (1–42)

0.38

Median number of PA LNs dissected

1 (1–29)

1 (1–25)

0.22

Positive peritoneal cytology

9 (3%)

13 (12%)

0.66

132 (37%)

41 (39%)

0.80

 Pelvic external beam alone

39 (11%)

15 (14%)

0.01

 Vaginal brachytherapy alone

195 (55%)

72 (68%)

 Combination

120 (34%)

15 (14%)

33 (9%)

19 (18%)

Lower uterine segment involvement
Radiation treatment modality

Tumor recurrence

0.01

Sites of first recurrence*
 Isolated vaginal recurrence

1 (3%)

6 (32%)

0.05

 Isolated pelvic recurrence

2 (6%)

0 (0%)

0.47

 Vaginal and pelvic recurrence

1 (3%)

1 (5%)

1.00

4 (12%)
25 (76%)

2 (11%)
10 (52%)

0.62
0.09

 Any PA LN recurrence without distant recurrence
 Any distant recurrence

*The listed percentage is a function of all recurrences within the same group.
AA, African American; BMI, body mass index; FIGO, International Federation of Gynecology and Obstetrics; LN, lymph node; LVSI,
lymphovascular space invasion; PA, para-aortic.

METHODS
After institutional review board approval, we searched our prospectively maintained institutional database for patients with endometrioid endometrial cancer, 2009 International Federation of Gynecology and Obstetrics stages I–II, who received adjuvant radiation
therapy alone after hysterectomy from January 1990 to September
2019. Patients who received adjuvant chemotherapy and those
with synchronous malignancies were excluded from the analysis.
Adjuvant radiation therapy was delivered based on the recommendations of our weekly gynecologic oncology tumor board in the
2

form of high-dose rate vaginal cuff brachytherapy, pelvic external
beam radiotherapy (via three-dimensional conformal or intensity-
modulated technique), or a combination of both modalities, based
on risk factors. Radiation doses were determined based on recommendations from international guidelines.10 11
In addition to the details of adjuvant radiation therapy, information on patient demographics, body mass index, baseline Charlson
comorbidity index at the time of hysterectomy, date of surgery,
tumor characteristics, and follow-up care was also obtained. The
time interval variable was calculated from the date of surgery to the
Zhu S, et al. Int J Gynecol Cancer 2020;0:1–5. doi:10.1136/ijgc-2020-001937
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Figure 1 Kaplan–Meier curve for recurrence-free survival of
the cohort at 5 years.

date of the first fraction of adjuvant radiation therapy. Based on the
time interval, patients were classified into two groups: time interval
≤8 weeks (group A) and >8 weeks (group B).
Survival endpoints for the study cohort, including recurrence-free
survival, disease-specific survival, and overall survival, were calculated with the Kaplan–Meier method for each group of patients.
The endpoints for each group were compared using the log-rank
test, and a two-sided p value of <0.05 was considered statistically significant. Univariate and multivariate analyses were also
performed for each survival endpoint. The Cox regression model
was used for multivariate analysis using manual stepwise selection
with an entry criterion of p<0.1 and stay criteria of p<0.05. Statistical analyses were performed using SAS 9.4 (Cary, North Carolina,
USA).
RESULTS
A total of 460 women were identified and included for analysis.
Median follow-up duration was 70.5 months (range 1–360) and
median age at the time of radiation treatment was 66 years (range
26–91). Three hundred and fifty-
four women (77%) received

Figure 2 Kaplan–Meier curve for overall survival of the
cohort at 5 years.
Zhu S, et al. Int J Gynecol Cancer 2020;0:1–5. doi:10.1136/ijgc-2020-001937

Figure 3 Kaplan–Meier curve for disease-specific survival
of the cohort at 5 years.

adjuvant radiation therapy within 8 weeks after hysterectomy
(group A). Except for some differences in the distribution of adjuvant radiation therapy modality (pelvic vs vaginal brachytherapy
vs combination), there was no statistically significant difference
between the two study groups in terms of patient demographics,
disease and treatment characteristics (Table 1).
The median time interval to adjuvant radiation therapy was 5.9
weeks (range 3.6–8) for group A and 9.7 weeks (range 8.1–25)
for group B (p<0.001). Of the 106 patients with time to radiation
therapy >8 weeks, only eight (5.7%) had time to radiation therapy
>15 weeks. The exact reason for the delays in the initiation of adjuvant radiation therapy was not routinely documented in the medical
records; however, the delay was most commonly due to medical
comorbidities or logistical reasons such as medical insurance
coverage and transportation issues.
A total of 52 patients experienced recurrences. Patients who
received adjuvant radiation therapy within 8 weeks after hysterectomy (group A) experienced significantly fewer recurrences overall
(9% vs 18%; p=0.014) compared with those who received adjuvant
radiation therapy >8 weeks (group B). The rate of isolated recurrences in the vagina was significantly lower in group A (3% vs 32%,
p=0.05) (Table 1). Patients in group A had a significantly higher
5-year recurrence-free survival compared with group B (89% vs
80%, p=0.04). The Kaplan–Meier curve of recurrence-free survival
for each group is shown in Figure 1. Univariate analysis showed
that delaying adjuvant radiation therapy by >8 weeks post hysterectomy (p=0.04), higher grade (p=0.0007), and the presence of
lymphovascular space invasion (p≤0.0001) were associated with
significantly worse 5-year recurrence-free survival.
The 5-year disease-specific survival was similar between groups
A and B (93% vs 93%, p=0.94) (Figure 2). Univariate analysis showed
that only higher grade (p<0.0001) and lymphovascular space invasion (p<0.0001) were associated with significantly worse 5-year
disease-specific survival. The 5-year overall survival was similar
between groups A and B (86% vs 85%, p=0.88) (Figure 3). Univariate analysis showed that more advanced age (p=0.002), higher
grade (p<0.0001), lymphovascular space invasion (p=0.0008), and
higher stage (p=0.018) were associated with significantly worse
5-year overall survival. The detailed results of multivariate analysis for recurrence-free, disease-specific, and overall survival are
3
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Table 2 Multivariate analysis for survival end points for the study cohort
Variables

Recurrence-free survival

Overall survival

HR

Grade

95% CI of HR

P value

HR

Disease-specific survival

95% CI of HR

P value

HR

95% CI of HR

P value

 

 

 

 

 

 2 vs 1

1.09

0.51 to 2.31

0.83

1.04

0.50 to 2.17

0.92

1.23

0.29 to 5.18

0.77

 3 vs 1

3.09

1.52 to 6.28

0.00

3.45

1.73 to 6.89

0.04

9.77

2.87 to 33.24

0.01

 

 

 

 

 

1.97 to 6.18

<0.0001 2.70

2.85 to 15.32

<0.0001

 

 

 

 

LVSI
 Positive vs negative

3.49

Time to ART

1.57 to 4.65

0.03

6.61

 

 >8 vs ≤8 weeks

1.72

0.96 to 3.11

0.07

N/A

N/A

N/A

N/A

N/A

N/A

Age

N/A

N/A

N/A

1.04

1.02 to 1.07

0.01

N/A

N/A

N/A

Charlson comorbidity
index

N/A

N/A

N/A

1.17

1.02 to 1.34

0.02

N/A

N/A

N/A

 

 

 

 

 

 IA vs IB

N/A

N/A

N/A

1.39

0.72 to 2.66

0.33

N/A

N/A

N/A

 IB vs II

N/A

N/A

N/A

2.43

1.21 to 4.88

0.013

N/A

N/A

N/A

FIGO stage

ART, adjuvant radiation therapy; FIGO, International Federation of Gynecology and Obstetrics; LVSI, lymphovascular space invasion;
N/A, not applicable as it was not included in the multivariate analysis.

shown in Table 2. Independent predictors of worse recurrence-free
survival included higher tumor grade and lymphovascular space
invasion. Independent predictors of worse overall survival included
older age, higher tumor grade, advanced stage, and the presence
of lymphovascular space invasion. Independent predictors of worse
disease-specific survival included higher tumor grade and lymphovascular space invasion.

DISCUSSION
For women with early-stage endometrial cancer of endometrioid
histology, in agreement with the general conclusion of previously
published reports,5–7 our results suggest that delaying adjuvant
radiation therapy beyond 8 weeks after hysterectomy is associated
with a higher risk of endometrial cancer recurrence, particularly in
the vagina. The 5-year recurrence-free survival was 9% higher for
the group who received adjuvant radiation therapy within 8 weeks
of hysterectomy (89% vs 80%, p=0.04). On univariate analysis for
factors predictive of higher recurrence rate, delaying adjuvant radiation therapy beyond 8 weeks was associated with increased recurrence rates (p=0.01). However, this statistically significant impact
for time interval was lost on multivariate analysis when accounting
for traditional prognostic factors such as higher tumor grade and the
presence of lymphovascular space invasion. This finding perhaps
suggests that the study is underpowered to show an independent,
statistically significant impact of the time interval to adjuvant radiation therapy. Nevertheless, the time interval to adjuvant radiation
therapy (>8 vs ≤8 weeks) trended toward statistical significance
(HR 1.72; 95% CI 0.96 to 3.11; p=0.07) on multivariate analysis
for 5-year recurrence-free survival. The improvement in 5-year
recurrence-free survival did not translate into similar improvement
in 5-year disease-specific survival and 5-year overall survival. This
could be attributed to the high salvage rate of recurrent endometrial
cancer12 13 and the fact that the most common cause of death in
4

women with early-stage endometrial cancer is usually not uterine
cancer.14
The main goal for adjuvant radiation therapy in women with endometrial cancer and higher risk of disease recurrence is to eradicate
remaining cancer cells following hysterectomy before cell repopulation and subsequent regional or distant spread occurs. Delivering
adjuvant radiation therapy in a timely manner would, at least in
theory, reduce the risk of loco-regional recurrence and improve
survival endpoints, as reported by some investigators.15 The
potential benefit of starting adjuvant radiation therapy on time has
been demonstrated in other disease sites (such as breast, central
nervous system, and head and neck) as well, where several studies
showed that delaying the initiation of adjuvant radiation therapy
was generally associated with less favorable outcomes.16–20
With the known limitations of the National Cancer Database such
as lack of information about tumor recurrence,21–23 the prognostic
significance of the time interval to adjuvant radiation therapy was
examined in two large studies that queried the National Cancer
Database. Luo et al8 included 28 824 women with stages I–II who
received adjuvant therapy (radiation therapy or chemotherapy or
both) after hysterectomy for endometrial cancer. The investigators
reported improved rate of overall survival in women who received
adjuvant therapy within 1.6 months (~6 weeks) compared with
those who received delayed adjuvant therapy beyond 1.6 months.
Similarly, Ghanem et al9 included 16 520 women with stage I and
II endometrioid uterine carcinoma who received adjuvant radiation therapy after hysterectomy. The investigators reported that a
delay in adjuvant radiation therapy of >8 weeks after hysterectomy
was associated with worse 5-year overall survival (p=0.048), even
though it was not an independent predictor for overall survival.9
Minimally invasive hysterectomy has emerged as the predominant surgical modality for patients with endometrial cancer
secondary to its favorable outcomes.24 The relatively higher risk of
vaginal dehiscence associated with this surgical approach25–27 may
Zhu S, et al. Int J Gynecol Cancer 2020;0:1–5. doi:10.1136/ijgc-2020-001937
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call for a delay in starting adjuvant radiation therapy and therefore
makes our finding particularly clinically relevant.
Our study has some limitations. The retrospective nature is
associated with inherent biases. The study is also limited by the
heterogeneity of treatment due to the time span over which the
patients were treated—over the period of well over three decades
the techniques of surgery and radiation therapy have significantly
changed. However, to avoid some of the limitations of other studies,
we only included a relatively uniform group of women with early-
stage disease, solely of endometrioid histology, who did not receive
adjuvant chemotherapy. Additionally, we have used our prospectively maintained database that is regularly audited and updated
and includes detailed information on patterns of recurrences.

CONCLUSIONS
In women with early-stage uterine endometrioid carcinoma, our
study suggests that delaying adjuvant radiation treatment beyond
8 weeks after hysterectomy is associated with significantly more
cancer recurrence. Our results should be validated in a large multi-
institutional pooled analysis. Until then, one should advocate for
timely initiation of adjuvant radiation therapy.
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